Clinical Trial Update: Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma

View source ↗

Summary

This update describes a study aimed at defining an immune signature that predicts response to anti-PD-1 antibodies in advanced melanoma. The goal is to improve …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Anti-PD-1 antibody

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Malignant Melanoma | Status: UNKNOWN